★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Bristol-Myers Squibb Company (BMY) Moat Analysis
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Bristol-Myers Squibb is a global biopharmaceutical company selling branded medicines across cardiovascular, oncology, hematology, immunology and neuroscience. Its defensible advantages are mainly product-level patent and regulatory exclusivity on key drugs such as Eliquis, Opdivo/Opdualag, Reblozyl and Sotyktu, plus specialized manufacturing capability in biologics and CAR-T. Durability is uneven: Revlimid and Pomalyst are eroding quickly from generics, Eliquis faces U.S. Medicare price pressure in 2026 and expected U.S. generic entry in 2028, and Orencia was selected for Medicare negotiation beginning in 2028. Formulary access is continuously renegotiated and specialized-drug persistence does not by itself prove switching or procurement inertia, so those moat claims are removed. Sustaining clinical differentiation and access is as important as IP.
Primary segment
Eliquis franchise (apixaban)
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
5 segments · 7 tags
Updated 2026-07-12
Segments
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Revenue
30%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Immune checkpoint inhibitors (PD-1/CTLA-4/LAG-3) for solid-tumor oncology
Revenue
29.8%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Hematology (Revlimid/Pomalyst/Reblozyl)
Hematology therapeutics (multiple myeloma regimens; anemia in MDS/beta-thalassemia)
Revenue
16.6%
Structure
Competitive
Pricing
weak
Share
—
Peers
Immunology (Orencia/Sotyktu)
Immunology therapies for rheumatoid/psoriatic arthritis and plaque psoriasis
Revenue
8.3%
Structure
Competitive
Pricing
weak
Share
—
Peers
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Specialty pharmaceuticals across cell therapy (CAR-T), cardiomyopathy, neuroscience, oncology, transplantation, and mature brands
Revenue
15.3%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Moat Claims
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Revenue share derived from FY2025 'Total Revenues by Product' table; Eliquis FY2025 total revenues were $14.443B of $48.195B total.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patent/regulatory exclusivity protects U.S. sales until a 2028 settlement-based generic entry, while EU generics have begun launching in certain countries before patent/SPC disputes are fully resolved.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Generic entry timing (U.S. 2028; EU earlier in some countries)
- Government pricing rules and payer rebate pressure
- Clinical differentiation vs rival DOACs
Leading indicators
- ANDA/court docket updates for apixaban patents
- Net price (gross-to-net) trend for Eliquis
- EU generic penetration by country
Counterarguments
- DOAC choice is heavily influenced by payer formularies; PBMs can switch preferred products quickly
- Competitors can win share via contracting or new data in key indications
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Immune checkpoint inhibitors (PD-1/CTLA-4/LAG-3) for solid-tumor oncology
Revenue share derived from FY2025 revenues for Opdivo ($10.049B), Opdivo Qvantig ($0.238B), Yervoy ($2.900B) and Opdualag ($1.185B).
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Core brands are protected by patent/regulatory exclusivity (Opdivo U.S. planning date 2028; Opdualag longer; Yervoy closer to LOE), supporting premium pricing while labels remain differentiated.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Loss of exclusivity for older IO assets (e.g., Yervoy)
- Clinical trial outcomes or label changes favoring competitors
- Next-generation IO modalities (bispecifics, ADC combos) shifting standards of care
Leading indicators
- New indications/label expansions and guideline updates
- Competitor trial readouts in key tumor types
- Price/rebate trend in oncology channels
Counterarguments
- Competitors with larger IO franchises can outspend or out-contract in oncology
- Rapidly evolving standards of care can flip market share on new data
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Biologics manufacturing is complex and highly regulated; BMS operates a global manufacturing network and can produce Opdivo internally and via qualified third parties to meet demand.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Manufacturing quality failures, recalls, or regulatory enforcement
- Input constraints (specialized materials) or single-source dependencies
- Biologics biosimilar manufacturing capabilities catching up
Leading indicators
- FDA/EMA inspection outcomes and warning letters
- Capacity expansion milestones for biologics/cell therapy sites
- Reported supply disruptions or backorders
Counterarguments
- Most large pharma can access biologics manufacturing via internal plants or CMOs; advantage may be incremental
- Supply capability does not guarantee clinical differentiation or market share
Hematology (Revlimid/Pomalyst/Reblozyl)
Hematology therapeutics (multiple myeloma regimens; anemia in MDS/beta-thalassemia)
Revenue share derived from FY2025 revenues for Revlimid ($2.951B), Pomalyst/Imnovid ($2.733B) and Reblozyl ($2.327B). Q1 FY2026 revenue declined sharply for Revlimid and Pomalyst as generic erosion accelerated.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Legal exclusivity is mixed and weakening: Revlimid volume-limited U.S. generic licenses ended January 31, 2026; Pomalyst now faces generic erosion; Reblozyl has longer regulatory/patent protection.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Generic/biosimilar entry accelerating price and volume declines
- Newer modalities in myeloma (CAR-T, bispecifics) displacing IMiDs
- Payer pressure as multiple alternatives exist
Leading indicators
- Generic launch/volume data for lenalidomide and pomalidomide
- NCCN/ESMO guideline shifts and new trial readouts
- Net sales trajectory by product (Revlimid vs Reblozyl mix)
Counterarguments
- Much of the franchise is already in decline due to generics; moat may be mostly harvested, not defended
- Treatment paradigms are moving to newer modalities where BMS is not the leader
Immunology (Orencia/Sotyktu)
Immunology therapies for rheumatoid/psoriatic arthritis and plaque psoriasis
Revenue share derived from FY2025 revenues for Orencia ($3.705B) and Sotyktu ($0.291B).
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Orencia retains formulation/additional patents through 2026+ with no known biosimilar on market per company disclosure; Sotyktu has longer patent runway (U.S. 2033 with potential extensions).
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Biosimilar entry for Orencia after patent expiry
- Government-set Medicare pricing for Orencia beginning in 2028
- High competition and payer step edits in immunology
Leading indicators
- Biosimilar filings and litigation outcomes for abatacept
- Sotyktu prescription growth vs rival oral/systemic agents
- Formulary positioning in commercial and Medicare channels
Counterarguments
- Immunology markets are highly rebate-driven; payer decisions can override clinical preference
- Multiple differentiated alternatives reduce the durability of any one brand's position
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Specialty pharmaceuticals across cell therapy (CAR-T), cardiomyopathy, neuroscience, oncology, transplantation, and mature brands
Revenue share is the residual of FY2025 total revenues after major franchises; includes Breyanzi, Camzyos, Zeposia, Abecma, Krazati, Augtyro, Cobenfy and mature brands like Sprycel/Abraxane.
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
CAR-T and other advanced modalities require specialized manufacturing infrastructure and quality systems; BMS has invested in a multi-site cell therapy network and received FDA approval for a commercial CAR-T facility.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Manufacturing deviations causing supply interruptions
- Competitors scaling superior CAR-T products
- Input shortages (vectors, specialized materials)
Leading indicators
- Facility buildout/expansion milestones and throughput
- Regulatory inspection outcomes
- Commercial CAR-T capacity utilization and lead times
Counterarguments
- Contract manufacturers can lower entry barriers over time
- Clinical superiority, not manufacturing alone, determines winner-take-most in CAR-T
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
This portfolio includes newer assets with multi-year exclusivity (e.g., Abecma, Breyanzi, Camzyos, Zeposia) which supports premium specialty pricing while differentiated and protected.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent litigation losses or earlier-than-expected generic entry
- Rapid competitive innovation in specialty niches
- Reimbursement tightening for high-cost specialty therapies
Leading indicators
- Patent/SPC litigation updates and Orange Book challenges
- New specialty product launches and trial readouts
- Coverage and prior-authorization changes
Counterarguments
- Specialty markets can shift quickly with new data; exclusivity does not ensure dominance
- Regulators and payers may limit uptake even when IP is intact
Evidence
...settlement agreements... generic companies... are permitted to launch in 2028...
Anchors the U.S. loss-of-exclusivity timing for the franchise.
In the EU, the apixaban ... patents and related SPCs expire in 2026.
Shows earlier EU patent/SPC expiry vs the U.S.; the 10-K also reports generic manufacturers have begun marketing in certain European countries.
Opdivo (nivolumab) 2028 ... Opdualag ... 2034 ... Yervoy ... 2025.
Shows that exclusivity windows are finite and vary by brand within the IO franchise.
Our IO products, particularly Opdivo, operate in a highly competitive marketplace.
Explains why legal exclusivity alone may not guarantee share; differentiation must be maintained.
Pharmaceutical manufacturing processes are complex, highly regulated...
Supports that scale/know-how in biologics manufacturing is a real capability barrier.
Showing 5 of 15 sources.
Risks & Indicators
Erosion risks
- Generic entry timing (U.S. 2028; EU earlier in some countries)
- Government pricing rules and payer rebate pressure
- Clinical differentiation vs rival DOACs
- Loss of exclusivity for older IO assets (e.g., Yervoy)
- Clinical trial outcomes or label changes favoring competitors
- Next-generation IO modalities (bispecifics, ADC combos) shifting standards of care
Leading indicators
- ANDA/court docket updates for apixaban patents
- Net price (gross-to-net) trend for Eliquis
- EU generic penetration by country
- New indications/label expansions and guideline updates
- Competitor trial readouts in key tumor types
- Price/rebate trend in oncology channels
Research BMY elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.